Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04327700 · ClinicalTrials.gov registry record · Phase 2
Study Of Intrabucally Administered Electromagnetic Fields and Regorafenib
A Phase 2 study, sponsored by Wake Forest University Health Sciences.
- Terminated
- Registry status
- Phase 2
- Development phase
- 2
- Enrollment target
NCT04327700 is a Phase 2 study that was terminated before completion, run by Wake Forest University Health Sciences. The registered enrollment target is 2 participants.
The verdict
NCT04327700, a Phase 2 study, was terminated before completion, sponsored by Wake Forest University Health Sciences.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 2 participants
- Enrollment target
Study Summary
The primary goal of this study is to gather efficacy data concerning the progression-free survival rate with electromagnetic fields plus Regorafenib when compared to historical data with Regorafenib alone as a second-line therapy in patients with advanced hepatocellular carcinoma who have received any first line systemic therapy either standard of care Sorafenib or Lenvatinib or any experimental therapy. Patients who have received any treatment that includes either electromagnetic fields or Regorafenib will be excluded.
Interventions
- DRUG Regorafenib
- DEVICE TheraBionic
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2021-01-26 |
| Est. Completion | 2024-05-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04327700
The ClinicalTrials.gov registry entry for NCT04327700 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 2 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Wake Forest University Health Sciences, which has 1,140 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Regorafenib is the first listed.
NCT04327700 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04327700 about?
NCT04327700 is a clinical study titled "Study Of Intrabucally Administered Electromagnetic Fields and Regorafenib". The primary goal of this study is to gather efficacy data concerning the progression-free survival rate with electromagnetic fields plus Regorafenib when compared to historical data with Regorafenib alone as a second-line therapy in patients with advanced hepatocellular carcinoma who have received a...
What is the current status of trial NCT04327700?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 2 participants. The study started on 2021-01-26. Estimated completion is 2024-05-31.
What interventions are being tested in trial NCT04327700?
The interventions under investigation include: Regorafenib (DRUG), TheraBionic (DEVICE).
Who is sponsoring clinical trial NCT04327700?
This trial is sponsored by Wake Forest University Health Sciences, which has 1,140 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.